Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: nelfinavir mesylate

« Back to Dashboard
Nelfinavir mesylate is the generic ingredient in one branded drug marketed by Agouron and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for nelfinavir mesylate. Five suppliers are listed for this compound.

Summary for Generic Name: nelfinavir mesylate

Drug Master File Entries: see list3
Suppliers / Packaging: see list8
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for Ingredient: nelfinavir mesylate

Drug ClassProtease Inhibitor
Mechanism of ActionHIV Protease Inhibitors

Clinical Trials for: nelfinavir mesylate

Nelfinavir, a Phase I/Phase II Rectal Cancer Study
Status: Completed Condition: Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal

Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer
Status: Active, not recruiting Condition: Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer

Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
Status: Recruiting Condition: Pancreatic Adenocarcinoma; Resectable Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
Status: Recruiting Condition: Multiple Myeloma

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Status: Completed Condition: HIV Infection

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Status: Recruiting Condition: Myeloma

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
Status: Terminated Condition: Adult Liposarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Status: Completed Condition: Leukemia; Lymphoma; Mature T-cell and Nk-cell Neoplasms; Multiple Myeloma and Plasma Cell Neoplasm

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
Status: Recruiting Condition: Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Kaposi Sarcoma; Gastric Cancer; Nasopharyngeal Cancer; EBV; Castleman Disease

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer
Status: Completed Condition: Cervical Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
nelfinavir mesylate
TABLET;ORAL021503-001Apr 30, 2003RXYes<disabled><disabled>
nelfinavir mesylate
TABLET;ORAL020779-001Mar 14, 1997RXYes<disabled><disabled>
nelfinavir mesylate
POWDER;ORAL020778-001Mar 14, 1997DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn